Report of Foreign Issuer (6-k)
June 08 2017 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of
1934
For the Month of June 2017
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv, 6578315, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted byRegulation S-T Rule 101(b)(7):
☐
On June 7,
2017, Galmed Pharmaceuticals Ltd. (the “Company”), held its Annual General Meeting of Shareholders
(the “Meeting”). At the Meeting, the Company’s shareholders voted on proposals to (i) re-elect Messrs.
Chaim Hurvitz and William Marth as Class III directors to serve as members of the board of directors (the
“Board”) until the annual general meeting to be held in 2020; (ii) elect Prof. Ran Oren as a Class II director to
serve as a member of the Board until the close of the annual general meeting to be held in 2019; (iii) elect Dr. Carol L.
Brosgart as a Class I director to serve as a member of the Board until the close of the annual general meeting to be held in
2018; (iv) re-elect Ms. Tali Yaron-Eldar and Dr. David Sidransky as the Company’s external directors for a term of
three years, commencing as of June 12, 2017; (v) approve the compensation terms for directors of the Company; (vi)
approve the terms of office and employment of the Company’s president and chief executive officer, Mr. Allen Baharaff;
(vii) approve an annual cash bonus and related objectives and terms thereof for 2017 for Mr. Allen Baharaff; (viii) approve
the Company’s directors and officers compensation policy; (ix) appoint Brightman Almagor Zohar & Co., a member firm
of Deloitte Touche Tohmatsu Limited, as the Company’s independent registered public accounting firm until the 2018
annual general meeting of shareholders, each as described in the proxy statement for the Meeting filed by the Company with
the Securities and Exchange Commission as an exhibit to the Company’s report on Form 6-K on April 27, 2017. The
proposals brought before the shareholders at the Meeting have been approved by the shareholders of the Company by the
requisite majority in accordance with the Israeli Companies Law, 5759-1999.
This Form 6-K is incorporated
by reference into the Company’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August
11, 2015 (Registration No. 333-206292) and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission
on March 31, 2015 (Registration No. 333-203133).
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
|
|
Date: June 8, 2017
|
By:
|
/s/ Allen Baharaff
|
|
|
Allen Baharaff
|
|
|
President and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024